GoodRx (NASDAQ:GDRX) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• GoodRx Holdings, Inc. experienced an unusual trading volume of over 5 million shares, increasing by 171% from the previous session, with its stock currently trading at $4.89.
• Multiple analyst ratings have been adjusted, with Goldman Sachs lowering its price target from $6.00 to $5.00, while UBS and Wells Fargo have also revised their targets, indicating a generally cautious outlook.
• The company reported a quarterly earnings miss, with an EPS of $0.09 against expectations of $0.10, contributing to ongoing concerns about its financial performance.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) shares saw strong trading volume on Tuesday . 5,003,278 shares traded hands during mid-day trading, an increase of 171% from the previous session's volume of 1,849,519 shares.The stock last traded at $4.89 and had previously closed at $5.12.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Raymond James Financial downgraded shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. The Goldman Sachs Group cut their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. UBS Group cut their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, Wells Fargo & Company cut their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $5.80.

GoodRx Trading Up 1.6%

The company has a fifty day simple moving average of $4.58 and a 200-day simple moving average of $4.50. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of 45.60, a P/E/G ratio of 1.99 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The business had revenue of $203.07 million during the quarter, compared to analyst estimates of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. GoodRx's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS. On average, research analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.53% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of GoodRx by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 8,624,872 shares of the company's stock valued at $38,036,000 after purchasing an additional 251,833 shares during the period. Ameriprise Financial Inc. grew its stake in shares of GoodRx by 4.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company's stock valued at $24,001,000 after buying an additional 184,734 shares in the last quarter. Petrus Trust Company LTA grew its stake in shares of GoodRx by 7.4% in the 1st quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company's stock valued at $13,967,000 after buying an additional 216,926 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock valued at $9,264,000 after buying an additional 369,553 shares in the last quarter. Finally, 8 Knots Management LLC bought a new stake in shares of GoodRx in the 1st quarter valued at approximately $8,106,000. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.